Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer

Abstract Background Immune checkpoint inhibitor (ICI) therapies represent a major advance in treating a variety of advanced-stage malignancies. Nevertheless, only a subset of patients benefit, even when selected based on approved biomarkers such as PD-L1 and tumor mutational burden. New biomarkers a...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Harsha Ranganath, Amit L. Jain, Justin R. Smith, Julie Ryder, Amina Chaudry, Emily Miller, Felicia Hare, Poojitha Valasareddy, Robert S. Seitz, David R. Hout, Matthew G. Varga, Brock L. Schweitzer, Tyler J. Nielsen, Janice Mullins, Douglas T. Ross, David R. Gandara, Gregory A. Vidal
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMC 2022-04-01
Saila:BMC Cancer
Gaiak:
Tumor biomarkers
Immunotherapy
Gene expression profiling
Programmed death ligand 1
Tumor microenvironment
Sarrera elektronikoa:https://doi.org/10.1186/s12885-022-09470-y
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak